Radiation therapy firm North American Scientific (NAS) said that the Advisory Committee on the Medical Uses of Isotopes to the U.S. Nuclear Regulatory Commission (NRC) has completed its review of its low-dose-rate breast brachytherapy treatment.
The committee unanimously agreed that it did not have a material concern about radiation risk to patients or the general public from the treatment, provided established patient release criteria are followed by physicians, according to the Chatsworth, CA-based firm.
By AuntMinnie.com staff writers
May 8, 2006
Related Reading
NAS gets FDA 510(k) for low-dose breast Brachytherapy, April 26, 2006
NAS opens $4 million credit line, March 31, 2006
NAS launches breast brachytherapy initiative, March 21, 2006
NAS gets Nasdaq noncompliance notice, March 20, 2006
NAS cuts losses in Q1, March 10, 2006
Copyright © 2006 AuntMinnie.com